Molecular consequences of presenilin-1 mutation

Sam Gandy (), Jan Naslund and Christer Nordstedt
Additional contact information
Sam Gandy: Sir James McCusker Alzheimer Research Unit, University of Western Australia
Jan Naslund: Karolinska Institutet
Christer Nordstedt: AstraZeneca

Nature, 2001, vol. 411, issue 6838, 654-655

Abstract: Abstract Alzheimer's disease is characterized by accumulation in the brain of a family of insoluble amyloid peptides (Aβ peptides)1, which are produced as a result of the normal processing of β-amyloid precursor protein (β-APP). Russo et al.2 claim that a truncated Aβ peptide that lacks the first ten amino acids accumulates in the brains of patients carrying a mutant form of pre-senilin 1 (PS1), a protein that is involved in cleavage of β-APP. However, we have found that this same species is also overrepresented in Alzheimer's patients with mutations in β-APP itself3. Our findings do not support the conclusion of Russo et al. that pathogenic PS1 mutations may control cleavage of β-APP by β-secretase4,5.

Date: 2001
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/35079682 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:411:y:2001:i:6838:d:10.1038_35079682

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/35079682

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().